Rifaximin for maintenance therapy in antibiotic-dependent pouchitis - Wikidata - wikimedia - TriplyDB

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

http://www.wikidata.org/entity/Q21261868

about

Use of rifaximin in gastrointestinal and liver diseases Role of antibiotics for treatment of inflammatory bowel disease Application of a spontaneously closed protective stoma in an ileal pouch-anal anastomosis: a preliminary study.Diagnosis and management of postoperative ileal pouch disorders.Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases Pros and cons of antibiotic therapy for pouchitis.Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.The bacterial pathogenesis and treatment of pouchitis.Biologic properties and clinical uses of rifaximin.Pharmacotherapy for acute pouchitis.Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all?Role of intestinal bacteria in the pathogenesis of pouchitis.Clostridium difficile infection in the postcolectomy patient.Pouchitis: a practical guide Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence.Inflammatory pouch disease: The spectrum of pouchitis.An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome.Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.Rifaximin in the treatment of inflammatory bowel disease.The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus.The effect of rifaximin on gut flora and Staphylococcus resistance.

P2860

Q26740201-24FF81F1-535F-4EDC-A6C3-9423107AC379 Q26774552-136D42E8-FE33-4486-97D8-D84BF780B469 Q33464475-1FA75822-706A-4835-81C7-92C5D7C7132B Q34237313-FF16C39E-4553-40B1-9000-593EBD4734F9 Q35228714-F1F070B1-F8E1-4605-A2C2-787BF50083E8 Q35558415-88DBA219-4A44-40DD-AC41-80C312C32649 Q36533648-B0F06BA3-C240-4E97-A263-87EEFD12ACE6 Q37611860-F91E4502-A034-47F6-9AE3-DED9F85F3F39 Q37768415-DF44647E-B306-47A5-B5A5-57ECDC5039B8 Q37823330-84BB39C8-DE67-4C41-A553-97424D3F592F Q37827877-E1885374-FA1B-4F6D-B31E-C01C6274DEE2 Q37903194-4CACF794-9F8D-4EA2-89D2-098D84B944A7 Q38003046-898208B8-B8E2-4F0F-964E-476D6C42A815 Q38026395-DBE49F5F-5372-4BA4-9AAE-A907242F29DC Q38232120-F61C7CB0-BD3B-4CCC-84BA-F31179AB04FB Q38268703-0E41DC79-4E5B-44F0-8181-B04A87277290 Q38609112-90DC685D-8596-41AD-B059-118EEA2F7A34 Q38966995-FF022816-62A6-4CEB-9935-0892A300CEAA Q42425137-FE05A2F5-3DB0-4D8F-86F9-A8C425848E5C Q42644383-13AC9AC9-4821-45D4-BD3B-1F822AC1B9CF Q42952867-1A90A712-7F62-4969-B547-CEC98466F2AD Q43010964-2BB757D1-CC7C-4BCB-9EBC-51BFADCECCA9 Q53781806-89ABB133-FB03-4455-A0E9-E2105CBC51B3 Q54263702-D19EE4EB-9D81-446E-941B-ACA57E813482

P2860

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

http://www.wikidata.org/entity/Q21261868

description

2008 nî lūn-bûn

@nan

2008 թուականին հրատարակուած գիտական յօդուած

@hyw

2008 թվականին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@ast

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en-gb

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@nl

type

label

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@ast

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en-gb

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@nl

prefLabel

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@ast

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en-gb

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@nl

P1433

Q21261868-FE0076B6-02CD-4FDD-A2E0-E82EBC2C0F66

P1476

Q21261868-8E9457AC-F29F-4398-8BB9-413ACB090B15

P2093

Q21261868-362F036A-6806-40DF-9315-706B0221E15D

Q21261868-63D8C973-186A-4494-9CB4-143DAB671174

Q21261868-789B5851-9F09-482E-B944-1B38290A78A4

Q21261868-BC5D4267-C059-4CEF-BAAE-2D9C80880716

P2860

Q21261868-1BCE6BBD-EA50-46D4-9E0C-3E3BF6904CC3

Q21261868-20444DE2-42AB-4CB9-AC58-F95E3B8FE0D7

Q21261868-212671D7-2A32-40C8-8F90-36CC1D6F8830

Q21261868-225652F2-A0F2-4452-82FD-7AF326F74B17

Q21261868-39D134F0-4A56-4E9A-A71C-117159E1BC28

Q21261868-3EC0DC12-F38C-419A-B776-F050744B461C

Q21261868-5E5BD013-2BDC-4013-8F9B-6FA022C4F25C

Q21261868-5E9D8EB6-2C75-4114-A333-A80B2E558272

Q21261868-6A680FF5-17AC-44F1-B02C-28213126F457

Q21261868-6DD640D6-EBA3-4D92-BE35-180BFF27795F

P2888

Q21261868-4C6B9039-E53B-48F8-969A-968C0A79C806

P304

Q21261868-C33350DC-B3C3-4BB8-9438-B85701A87160

P31

Q21261868-22717252-6CC2-4AA4-B562-6AE95A899AF8

P356

Q21261868-D59DED7E-36D6-4BD9-B88E-29C01BC4CAA5

P407

Q21261868-B9E99847-7F7C-4288-9CFA-91FB4FE89AF1

P433

Q21261868-C55FFE44-FF48-4443-9D7B-215EFA124E61

P478

Q21261868-FD17B1CE-7C60-4304-8B96-D5105DD0F6FC

P577

Q21261868-256DA4ED-9A5A-435C-A169-79DC09FB8469

P6179

Q21261868-34FE16AF-41AC-4C3D-94FF-16DDBFB6AA11

P698

Q21261868-CEDD8C6C-7685-4380-B693-154512C21A37

P932

Q21261868-D5B717CA-FC76-4ACE-9DB2-6C95F2F38DD1

P356

P1433

BMC Gastroenterology

P1476

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

@en

P2093

A Rocio Lopez

http://www.w3.org/2001/XMLSchema#string

Bo Shen

http://www.w3.org/2001/XMLSchema#string

Elaine Queener

http://www.w3.org/2001/XMLSchema#string

Feza H Remzi

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and management of pouchitis

Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses.

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.

Clinical approach to diseases of ileal pouch-anal anastomosis.

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

Systematic review: the management of pouchitis.

Current and future developments in travelers' diarrhea therapy.

P2888

P304

26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-230X-8-26

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041563193

http://www.w3.org/2001/XMLSchema#string

P698

18573211

http://www.w3.org/2001/XMLSchema#string

P932

2442097

http://www.w3.org/2001/XMLSchema#string